Summary: AbbVie Inc. has rebounded from setbacks with a strong pipeline, including the promising Parkinson’s
jetcityimage BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly
vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) reported positive topline results from a Phase 3
As previously reported, BofA downgraded Alector (NASDAQ:ALEC) to Underperform from Neutral with a price target
Summary: AbbVie’s stock dropped 17.3% due to Emraclidine’s phase 2 trial failure, but management is
Galeanu Mihai J.P. Morgan analysts updated their “Analyst Focus List” which targets growth, income, value,
Summary: In recent days, financial market participants have remained pessimistic about AbbVie’s prospects, mainly due
hapabapa Leerink has upgraded AbbVie (NYSE:ABBV) to outperform from market perform, commenting that the recent
vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) shares snapped eight consecutive sessions of losses as
hapabapa Aldeyra Therapeutics (NASDAQ:ALDX) announced FDA acceptance of its resubmitted market application for topical ocular